Author:
Beumer Inès,Witteveen Anke,Delahaye Leonie,Wehkamp Diederik,Snel Mireille,Dreezen Christa,Zheng John,Floore Arno,Brink Guido,Chan Bob,Linn Sabine,Bernards Rene,van ’t Veer Laura,Glas Annuska
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. MammaPrint FDA clearance. See Decision Summary at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?ID=DEN070009
2. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn H-J (2015) Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533–1546
3. NCCN Clinical Practice Guidelines in oncology for Breast Cancer version 3.2015. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
4. Glas AM, Floore A, Delahaye LJMJ, Witteveen AT, Pover RCF, Bakx N, Lahti-Domenici JST, Bruinsma TJ, Warmoes MO, Wessels LFA, Veer LJV (2006) Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7:278
5. Drukker CA, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van’t Tinteren H, Wesseling J, Roumen RMH, Knauer M, van Veer LJ, Sonke GS, Rutgers EJT, van de Vijver MJ, Linn SC (2013) A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 133:929–936
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献